Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > So what if I told you

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jul 16, 2022 11:21am

116 Views

Post# 34828993

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:So what if I told you

If I am right about the idea that the company is about to go on acharm offensive with investors, we will be getting a nice shiny new corporate presentations soon too.

qwerty22 wrote:
It has been the case that when they update the investor presentation that they've put small details in that have clarified the situation for me. Given the loan they probably should update the presentation soon. Maybe there'll be a little extra clarity around the 1a data then. Maybe.

realitycheck4u wrote: He does and I felt that. We do not know if big pharma is or not. But with the entire call, the tone was just spot on. Thank you to everyone here explaining things in detail. I see now they do not have all the data and will release it when they do or should.

Momo25 wrote: Paul Levesque seems optimistic. Big pharma and investors are not. Apparently, the preliminary results are not enough convincing. I am expecting the next 3 months will be tough on a SP valuation. No buyers, no sellers except the bank algorithms dragging the share down It's a catch 22 situation.